Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

Biogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.

You May Also Be Interested In

• Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
• Rigetti Computing (RGTI) call put ratio 10.4 calls to 1 put with a focus on June 26 weekly 25 calls as share price up 2.8%
• Genco Shipping & Trading Limited (GNK) 8400 contracts of August 30 calls trade, share price up 5.5%